Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
- Muvon
- Jul 1
- 2 min read
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as Chairman of the Board of Directors.
MUVON Therapeutics, an award-winning, clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, today announced the appointment of Thomas Meier as the Chairman of its Board of Directors.
Dr Meier has over 25 years of entrepreneurial, strategic and operational experience leading innovative biopharmaceutical companies through transitional periods in their corporate development and to rapid growth. As founder and long-time executive manager and Board member of Santhera Pharmaceuticals he successfully executed merger/acquisitions, product licensing and turn-around situations. In 2020 Dr Meier became Managing Partner at Viopas Venture Consulting. He currently holds Board positions at several private and public pharma/biotech companies.
Thomas Meier commented, “I am honored to take on the role of Chairman of MUVON Therapeutics’ Board of Directors. The Company has a unique opportunity to leverage its innovative cell-based tissue engineering platform to treat diseases related to skeletal muscle damage, with an initial lead indication of stress urinary incontinence. I look forward to providing guidance and support MUVON’s management in their mission to improve the lives of millions of patients impacted by the effects of muscle tissue damage or degradation.”
Chris Jaeggi, outgoing founding Chairman of MUVON Therapeutics’ Board of Directors said “As the Company is moving into the next stage of growth, we are excited about the opportunities to expand the potential applications of the Company’s autologous tissue-engineering platform in additional therapeutic areas. I look forward to remaining a part of the MUVON family during this exciting time in the Company’s evolution and supporting the team to achieve its mission of helping patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatments for the regeneration of skeletal muscle tissue.”
For more information, please contact:
Dr Deana Mohr, CEO
About MUVON Therapeutics AG
Founded in 2020, MUVON Therapeutics is a clinical-stage life science spin-off from the University of Zurich currently being accelerated by the Wyss Zurich Translational Center. MUVON Therapeutics is dedicated to the discovery and development of personalized regenerative treatments with the goal of establishing them as an affordable standard of care, with an initial focus on the treatment of stress urinary incontinence in women. Our mission is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle tissue. For more information about MUVON Therapeutics, please visit: www.muvon-therapeutics.com
Comments